Bench-to-bedside review: Angiopoietin signalling in critical illness

cc7153 CCJ Review Bench-to-bedside review: Angiopoietin signalling in critical illness – a future target? van Meurs Matijs m.van.meurs@anest.umcg.nl Kümpers Philipp kuempers.philipp@mh-hannover.de Ligtenberg JM Jack j.j.m.ligtenberg@int.umcg.nl Meertens HJM John j.h.j.m.meertens@anest.umcg.nl Molema Grietje g.molema@med.umcg.nl Zijlstra G Jan j.g.zijlstra@int.umcg.nl

Department of Critical Care, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands

Department of Pathology and Medical Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen, HPC EA11, PO Box 30.001 9700 RB Groningen, The Netherlands

Department of Nephrology & Hypertension, Hanover Medical School, Carl-Neuberg-strasse 1, Hannover, D 30171, Germany

Critical Care 1364-8535 2009 13 2 207 http://ccforum.com/content/13/2/207 1943547610.1186/cc7153 9 3 2009 2009 BioMed Central Ltd

Abstract

Multiple organ dysfunction syndrome (MODS) occurs in response to major insults such as sepsis, severe haemorrhage, trauma, major surgery and pancreatitis. The mortality rate is high despite intensive supportive care. The pathophysiological mechanism underlying MODS are not entirely clear, although several have been proposed. Overwhelming inflammation, immunoparesis, occult oxygen debt and other mechanisms have been investigated, and – despite many unanswered questions – therapies targeting these mechanisms have been developed. Unfortunately, only a few interventions, usually those targeting multiple mechanisms at the same time, have appeared to be beneficial. We clearly need to understand better the mechanisms that underlie MODS. The endothelium certainly plays an active role in MODS. It functions at the intersection of several systems, including inflammation, coagulation, haemodynamics, fluid and electrolyte balance, and cell migration. An important regulator of these systems is the angiopoietin/Tie2 signalling system. In this review we describe this signalling system, giving special attention to what is known about it in critically ill patients and its potential as a target for therapy.

Introduction

Critical illness is a life-threatening disease by definition. Patients treated for critical illness in the intensive care unit have underlying causes such as infection, trauma, major surgery, hemorrhagic shock, pancreatitis and other major insults. Despite maximal supportive care, severely ill patients treated in intensive care units are still likely to die, usually after an episode of increasing failure of multiple organs 1.

The mechanisms that underlie multiple organ dysfunction syndrome (MODS) are not known 2, although several have been proposed, including overwhelming infection or immune response, immune paralysis, occult oxygen debt and mitochondrial dysfunction 345. Although these potential mechanisms have features in common, it is not clear whether MODS is a final common pathway or when it is engaged. The innate and adaptive immune systems, coagulation, and hormonal and neuronal signalling are undoubtedly involved and are all connected. For example, the hypoxic response is linked to innate immunity and inflammation by the transcription factor nuclear factor-κB (NF-κB) 6. It is no coincidence that the few interventions that appear to be of benefit, although this is still under debate, have pleiotropic mechanisms of action 789. Thus, it seems reasonable to study the intersections between and within cellular and molecular systems to elucidate the interactions and to develop therapeutic options.

One of the central cellular players in this system is the endothelial cell (EC). Once thought to serve as an inert vascular lining, ECs are highly heterogeneous and constitute an active disseminated organ throughout the circulatory system. ECs form the border between every organ and the bloodstream and thus with the rest of the body. The EC receives and gives signals, stores active substances of multiple systems, and regulates the passage of fluids, electrolytes, proteins and cells. The EC has a time and place dependent phenotype that is dynamically controlled, and its reactions to stimuli are specific to organ and vascular bed 10111213. The EC merits robust investigation in critical illness, as in vascular medicine 14.

ECs fulfil three functions. First, they participate in the formation of new blood vessels. This is important in embryogenesis and organogenesis in normal physiology and in wound repair, but it is considered pathologic in tumour growth and diabetes 15. Second, in the adult organism, ECs help to maintain homeostasis, including fluid, electrolyte and protein transport, and cell migration into and out of the vessel, and to regulate blood flow. Third, ECs react and respond to disturbances of homeostasis (for example, in inflammation, coagulation and hypoxia/reperfusion).

All three functions are involved in MODS, in which ECs are shed, blood flow regulation is hampered, vessels become leaky, cells migrate out of the vessel and into the surrounding tissue, and coagulation and inflammation pathways are activated 16. The machinery involved – receptors, signalling pathways and effectors – is largely the same in each function, but the net effect is determined by the balance between the parts of the machinery and the context 15.

The angiopoietin/Tie2 signalling system (Ang/Tie system) appears to be crucial in all three functions 1718. The Ang/Tie system, which was discovered after vascular endothelial growth factor (VEGF) and its receptors, is mainly restricted to EC regulation and is the focus of this review. Accumulating evidence suggests that this system is non-redundant and is involved in multiple MODS-related pathways. All components of potential pathophysiological mechanisms in MODS should be viewed within their own context, because all systems are mutually dependent. Thus, examination of the Ang/Tie system might offer insight into the mechanisms underlying MODS and provide opportunities for therapeutic intervention.

Is the Ang/Tie system involved in critical illness?

The notion that the Ang/Tie system contributes to disease pathogenesis is supported by clinical studies and studies in animal models, and by the relation between symptoms of critical illness and disturbances in this system. In mice, Ang-2 over-expression in glomeruli causes proteinuria and apoptosis of glomerular ECs 19. In a rat model of glomerulonephritis, Tie2 is over-expressed by ECs, and Ang-1 and Ang-2 are over-expressed by podocytes in a time-dependent manner during the repair phase 20. Therefore, Ang/Tie might be involved in renal failure and repair.

Lung dysfunction is common in critical illness, and evidence of Ang/Tie involvement has been found in animal models. In a rat model of acute respiratory distress syndrome, Ang-1 reduces permeability and inflammation, whereas Tie2 deficiency increases damage 21. In an experimental model of asthma, Ang-1 mRNA was decreased, and Ang-1 supplementation decreased alveolar leakage and NF-κB-dependent inflammation 22. In hypoxia-induced pulmonary hypertension in rats, decreased activity of the Tie2 pathway contributed to right ventricular load, and this effect was antagonized by Ang-1 23. On the other hand, a causative role for Ang-1 in pulmonary hypertension has also been suggested 24. In hyperoxic lung injury, Ang-2 is involved in lung permeability and inflammation 25.

Ang/Tie also may contribute to critical illness in patients with pulmonary conditions. Ang-1 and Ang-2 concentrations in sputum from asthma patients correlated with airway microvascular permeability 26. In patients with exudative pleural effusion, the Ang-2 level was increased whereas Ang-1 was unchanged 27. Ang-2 levels are associated with pulmonary vascular leakage and the severity of acute lung injury. Plasma from patients with acute lung injury and high Ang-2 concentrations disrupts junctional architecture in vitro in human microvascular ECs 2829.

Patients with cardiovascular disorders also exhibit changes in the Ang/Tie system. Circulating Ang-1 concentrations are stable in patients with atrial fibrillation, but Ang-2 concentrations are increased, along with markers of platelet activation, angiogenesis and inflammation 30. Patients with hypertension resulting in endorgan damage have increased levels of circulating Ang-1, Ang-2, Tie2 and VEGF 31. Congestive heart failure is associated with elevated plasma levels of Ang-2, Tie2 and VEGF, but normal levels of Ang-1 32. A similar pattern is seen in acute coronary syndrome 33.

Circulating levels of components of the Ang/Tie system have been measured in patients admitted to the critical care unit. In trauma patients plasma Ang-2, but not plasma Ang-1 or VEGF, was increased early after trauma, and the level correlated with disease severity and outcome 34. In children with sepsis and septic shock, Ang-2 levels in plasma were increased and once again correlated with disease severity, whereas Ang-1 levels were decreased 35. The same Ang-1/Ang-2 pattern is seen in adults with sepsis 282936373839. The results of studies of the Ang/Tie system in humans are summarized in Table 1. In sepsis, VEGF and its soluble receptor sFLT-1 (soluble VEGFR-1) are also increased in a disease severity-dependent manner 404142. The picture that emerges from these studies is that the Ang/Tie signalling system appears to play a crucial role in the symptoms of MODS. Findings in animal models and in patients suggest that Ang-1 stabilizes ECs and Ang-2 prepares them for action. The close relation with VEGF is also apparent.

Table 1

Clinical studies of Ang-1, Ang-2 and soluble Tie2 in critically ill patients

Study

Patients

Ang-1

Ang-2

Soluble Tie2

Clinical effects

Lee et al. 33

ACS: 82 AMI, 44 unstable angina, 40 stable CAD 40 HCs

Higher in AMI versus HCs, SA, unstable angina

Kugathasan et al. 23

PAH: 6 idiopathic, 7 with other disease 8 HCs

Tie2 mRNA higher in lung of PAH patients versus HCs

Parikh et al. 28

ICU patients: 17 severe sepsis, 5 mild sepsis 29 HCs

Higher in severe sepsis versus HCs

Ang-2 levels correlate with low PaO₂/FiO₂

Gallagher et al. 180

Vascular leakage: 14 IL-2, 14 IL-2+bevacizumab

Higher during therapy

Ang-2 levels rise on days of IL-2 therapy; high levels on day 3 predict vascular leakage (stop therapy)

Gallagher et al. 29

ARDS: 45 ICU, 18 ARDS

Higher in ARDS versus ICU patients; in ARDS, higher in nonsurvivors

High levels of Ang-2 on day patient meets ARDS criteria. Ang-2 levels in ARDS patients correlate with mortality

Giuliano et al. 35

Septic shock children: 20 SIRS 20 sepsis, 61 septic shock 15 HCs

Ang-1 lower in septic shock versus sepsis and SIRS

Higher in septic shock versus HCs, SIRS and sepsis

Orfanos et al. 37

ICU patients: 6 no SIRS, 8 SIRS, 16 sepsis, 18 severe sepsis, 13 septic shock

Higher in severe sepsis versus no SIRS and sepsis

Ang-2 levels related to severe sepsis and TNF-α levels

Scholz et al. 181

180 liver cirrhosis patients 40 HCs

Higher in cirrhosis versus HCs

Ganter et al. 34

208 trauma patients in ER

Unchanged

Higher within 30 minutes after ER admission

Ang-2 levels correlate with met ISS and mortality. Ang-2 higher in nonsurvivors

van der Heijden et al. 39

24 sepsis, 88 nonseptic critically ill 15 HCs

Ang-1 lower in sepsis and critical illness versus HCs

Higher in critically ill patients; higher in septic than nonseptic patients

Ang-2 levels associated with pulmonary permeability oedema and severity of ALI in septic and nonseptic critically ill patients

Lukasz et al. 36

94 critically ill medical ICU patients 30 HCs

Ang-1 correlated negatively with SOFA Score

Ang-2 correlates positively with SOFA Score

Ang-1 correlates negatively and Ang-2 positively with SOFA score

Siner et al. 38

Critically ill patients: 20 nonseptic (ICU), 10 sepsis, 12 severe sepsis, 24 septic shock

Ang-2 increases with severity of sepsis

Increase in Ang-2 associated with severity of illness and hospital mortality

ACS, acute coronary syndrome; AMI, acute myocardial infarction; ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; ER, emergency room; Fi oxygen; HC, healthy control; ICU, intensive care unit; IL, interleukin; ISS, International Severity Score; ND, not determined; NS, not significant; PAH, pulmonary arterial hypertension; Pa pulmonary artery oxygen tension; SA, stable angina; SOFA, Sequential Organ Failure Assessment score; TNF, tumour necrosis factor.

The angiopoietin signalling system

Ligands and receptors

The angiopoietin signalling system consists of four ligands and two receptors (Figure 1). The ligands are Ang-1 to Ang-4, the best studied being Ang-1 and Ang-2 17434445. The roles of Ang-3 (the murine orthologue of Ang-4) and Ang-4 are much less clear 18. Angiopoietins are 70-kDa glycoproteins that contain an amino-terminal angiopoietin-specific domain, a coiled-coil domain, a linker peptide and a carboxyl-terminal fibrinogen homology domain 17444647. Ang-1 and Ang-2 bind to Tie2 after polymerization of at least four (Ang-1) and two (Ang-2) subunits 4849. The dissimilarity between Ang-1 and Ang-2 signalling lies in subtle differences in the receptor binding domain that lead to distinct intracellular actions of the receptor; differential cellular handling of both receptor and ligands after binding and signalling initiation may also play a role 4950.

Figure 1

A schematic model of the angiopoietin-Tie2 ligand-receptor system

A schematic model of the angiopoietin-Tie2 ligand-receptor system. Quiescent endothelial cells are attached to pericytes that constitutively produce Ang-1. As a vascular maintenance factor, Ang-1 reacts with the endothelial tyrosine kinase receptor Tie2. Ligand binding to the extracellular domain of Tie2 results in receptor dimerization, autophosphorylation, docking of adaptors and coupling to intracellular signalling pathways. Signal transduction by Tie2 activates the PI3K/Akt cell survival signalling pathway, thereby leading to vascular stabilization. Tie2 activation also inhibits the NF-κB-dependent expression of inflammatory genes, such as those encoding luminal adhesion molecules (for example, intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin). Ang-2 is stored and rapidly released from WPBs in an autocrine and paracrine fashion upon stimulation by various inflammatory agents. Ang-2 acts as an antagonist of Ang-1, stops Tie2 signalling, and sensitizes endothelium to inflammatory mediators (for example, tumour necrosis factor-α) or facilitates vascular endothelial growth factor-induced angiogenesis. Ang-2-mediated disruption of protective Ang-1/Tie2 signalling causes disassembly of cell-cell junctions via the Rho kinase pathway. In inflammation, this process causes capillary leakage and facilitates transmigration of leucocytes. In angiogenesis, loss of cell-cell contacts is a prerequisite for endothelial cell migration and new vessel formation. Ang, angiopoietin; NF-κB, nuclear factor-κB; PI3K, phosphoinositide-3 kinase; WPB, Weibel-Palade body.

The receptors are Tie1 and Tie2 51. Tie2 is a 140-kDa tyrosine kinase receptor with homology to immunoglobulin and epidermal growth factor 4752. Tie receptors have an amino-terminal ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain 51. Ligand binding to the extracellular domain of Tie2 results in receptor dimerization, autophosphorylation and docking of adaptors, and coupling to intracellular signalling pathways 47535455. Tie2 is shed from the EC and can be detected in soluble form in normal human serum and plasma; soluble Tie2 may be involved in ligand scavenging without signalling 56. Tie2 shedding is both constitutive and induced; the latter can be controlled by VEGF via a pathway that is dependent on phosphoinositide-3 kinase (PI3K) and Akt 57. Shed soluble Tie2 can scavenge Ang-1 and Ang-2 56. Tie1 does not act as a transmembrane kinase; rather, it regulates the binding of ligands to Tie2 and modulates its signalling 585960.

Origin of ligands and distribution of receptors

Ang-1 is produced by pericytes and smooth muscle cells (Figure 1). In the glomerulus, which lacks pericytes, Ang-1 is produced by podocytes 61. Ang-1 has a high affinity for the extracellular matrix, and so circulating levels do not reflect tissue levels, which in part is probably responsible for the constitutive phosphorylation of Tie2 in quiescent endothelium 62636465. Ang-2 is produced in ECs and stored in Weibel-Palade bodies (WPBs) 6667. The release of Ang-2 from WPBs by exocytosis can be regulated independently of the release of other stored proteins 68. Tie2 is expressed predominantly by ECs, although some subsets of macrophages and multiple other cell types express Tie2 at low levels 6970. In ECs, Tie2 is most abundant in the endothelial caveolae 71.

Genetics and transcriptional regulation of components of the Ang/Tie system

The Ang-1 and Ang-2 genes are located on chromosome 8. Functional polymorphisms have not been identified in the Ang-1 gene, but three have been identified in the coding region of Ang-2 72. In ECs under stress, Ang-2 mRNA expression is induced by VEGF, fibroblast growth factor 2 and hypoxia 4473. Upregulation of Ang-2 induced by VEGF and hypoxia can be abolished by inhibiting tyrosine kinase or mitogen-activated protein kinase 73. Ang-2 mRNA expression can be downregulated by Ang-1, Ang-2, or transforming growth factor 74. After inhibition of PI3K by wortmannin, Ang-2 mRNA production is induced by the transcription factor FOXO1 (forkhead box O1) 75. EC-specific Ang-2 promoter activity is regulated by Ets-1 and the Ets family member Elf-1 7677. Because Tie2 signalling is required under circumstances that usually hamper cell metabolism, its promoter contains repeats that ensure transcription under difficult circumstances, including hypoxia 78.

The Tie2 downstream signalling pathway

Tie2 is present in phosphorylated form in quiescent and activated ECs throughout the body 62. Signalling is initiated by autophosphorylation of Tie2 after Ang-1 binding and is conducted by several distinct pathways 54717980. Tie2 can also be activated at cell-cell contacts when Ang-1 induces Tie2/Tie2 homotypic intercellular bridges 65. In human umbilical vein endothelial cells (HUVECs), Ang/Tie signalling resulted in 86 upregulated genes and 49 down-regulated genes 8182. Akt phosphorylation by PI3K with interaction of nitric oxide is the most important intracellular pathway 5183848586; however, ERK1/2, p38MAPK, and SAPK/JNK can also participate in Ang/Tie downstream signalling 71818487888990. Endothelial barrier control by Ang-1 requires p190RhoGAP, a GTPase regulator that can modify the cytoskeleton 80. The transcription factors FOXO1, activator protein-1, and NF-κB are involved in Ang/Tie-regulated gene transcription 75919293. Ang-1-induced signalling is has also been implicated in cell migration induced by reactive oxygen species 94. ABIN-2 (A20-binding inhibitor of NF-κB 2), an inhibitor of NF-κB, is involved in Ang-1-regulated inhibition of endothelial apoptosis and inflammation in HUVECs 93. However, the downstream signalling of Tie2 varies depending on cell type and localization and whether a cell-cell or cell-matrix interaction in involved, which results in spatiotemporally different patterns of gene expression. For example, Ang-1/Tie2 signalling leads to Akt activation within the context of cell-cell interaction, but it leads to ERK activation in the context of cell-matrix interaction. The microenvironment of the receptor in the cell membrane plays a central role in this signal differentiation. Adaptor molecules such as DOK and SHP2 and the availability of substrate determine which protein is phosphorylated 95.

Signal regulation

After binding of Ang-1, and to a lesser extent Ang-2, Tie2 is internalized and degraded, and Ang-1 is shed in a reusable form 50. VEGF is an important co-factor that can exert different effects on Ang-1 and Ang-2 signalling 88. Ang-2 is anti-apoptotic in the presence of VEGF but induces EC apoptosis in its absence 96. Autophosphorylation and subsequent signalling are inhibited by heteropolymerization of Tie1 and Tie2 59. Although the Ang/Tie system appears to play its role mainly in paracrine and autocrine processes, its circulating components have been found in plasma. The significance of this finding in health and disease has yet to be determined.

Summary

The Ang/Tie system is an integrated, highly complex system of checks and balances (Figure 1) 4554. The response of ECs to Ang-1 and Ang-2 depends on the location of the cells and the biological and biomechanical context 9798. It is believed that PI3K/Akt is among the most important downstream signalling pathways and that VEGF is one of the most important modulators of effects. Below we describe in more detail how this system responds to changes in homeostatic balances under various conditions of damage and repair.

Ang/Tie signalling system in health and disease

Angiogenesis, inflammation and homeostasis are highly related, and the Ang/Tie system lies at the intersection of all three processes 99100. The Ang/Tie system is critically important for angiogenesis during embryogenesis, but in healthy adults its function shifts toward maintenance of homeostasis and reaction to insults. Except for follicle formation, menstruation and pregnancy, angiogenesis in adults is disease related. Neoplasia-associated neoangio-genesis and neovascularization in diabetes and rheumatoid arthritis are unfavourable events, and improper angiogenesis is the subject of research in ischaemic disorders and atherosclerosis. Finally, failure to maintain homeostasis and an inappropriate reaction to injury are detrimental features in critical illness.

Angiogenesis

Angiogenesis is dependent on multiple growth factors and receptors and their signalling systems and transcriptional regulators 101. The process is complex and encompasses the recruitment of mobile ECs and endothelial progenitor cells, the proliferation and apoptosis of these cells, and reorganization of the surroundings 102. To form stable new blood vessels, the response must be coordinated in time and space, and the Ang/Tie system is involved from beginning to end. To prepare for angiogenesis, Ang-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism 44103. Before vascular sprouting starts, focal adhesion kinase and proteinases such as plasmin and metallo-proteinases are excreted 85. Often, this stage is preceded by activation of innate immunity and inflammation 104. Apparently, the machinery to clean up after the work has been finished is installed before the work is commenced, again illustrating the close relations among the different processes 104.

Ang-1 maintains and, when required, restores the higher order architecture of growing blood vessels 4344105106. This is achieved by inhibiting apoptosis of ECs by Tie2-mediated activation of PI3K/Akt signalling 107108109. Ang-1/Tie2 signalling is involved in angiogenesis induced by cyclic strain and hypoxia 110111. Although its role is less clear, Tie1 might be involved in EC reactions to shear stress 112. Ang-1 is a chemoattractant for ECs 838485, and both Ang-1 and Ang-2 have proliferative effects on those cells 98113. At the end of a vascular remodelling phase, Ang-2 induces apoptosis of ECs for vessel regression in competition with the survival signal of Ang-1 106. This apoptotic process requires macrophages, which are recruited by Ang-2 70114.

ECs require support from surrounding cells such as pericytes, podocytes, and smooth muscle cells 63. These cells actively control vascular behaviour by producing signalling compounds (for instance, Ang-1 and VEGF) that govern the activity and response of ECs 61. To attract ECs, Ang-1 secreted by support cells binds to the extracellular matrix. In quiescent ECs, this binding results in Tie2 movement to the site of cell-cell interaction. In mobile ECs, Ang-1 polarizes the cell with Tie2 movement abluminal site 65. In tumour angiogenesis and in inflammation, Ang-2 recruits Tie2-positive monocytes and causes them to release cytokines and adopt a pro-angiogenic phenotype 111.

Homeostasis

The Ang/Tie system provides vascular wall stability by inducing EC survival and vascular integrity. However, this stability can be disrupted by Ang-2 injection, which in healthy mice causes oedema 2879115116 that can be blocked by systemic administration of soluble Tie2 115. Ang-2 can impair homeostatic capacity by disrupting cell-cell adhesion through E-cadherin discharge and EC contraction 28117. In contrast, through effects on intracellular signalling, the cytoskeleton and junction-related molecules, Ang-1 reduces leakage from inflamed venules by restricting the number and size of gaps that form at endothelial cell junctions 80118119. Ang-1 also suppresses expression of tissue factor induced by VEGF and tumour necrosis factor (TNF)-α, as well as expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and E-selectin. As a result, endothelial inflammation is suppressed 120121122123.

In primary human glomerular ECs in vitro, Ang-1 stabilizes the endothelium by inhibiting angiogenesis, and VEGF increases water permeability 124. Similar observations were made in bovine lung ECs and immortalized HUVECs, in which Ang-1 decreased permeability, adherence of polymorphonuclear leucocytes and interleukin-8 production 123.

Injury

Reaction to injury can be seen as an attempt to maintain homeostasis under exceptional conditions. ECs can be affected by several noxious mechanisms. The Ang/Tie system is considered crucial in fine-tuning their reaction to injury and in containing that reaction. Ang-2-deficient mice cannot mount an inflammatory response to peritonitis induced chemically or with Staphylococcus aureus 125, but they can mount a response to pneumonia, suggesting the existence of inflammatory reactions for which Ang-2 is not mandatory. Ang-2 sensitizes ECs to activation by inflammatory cytokines. In Ang-2-deficient mice, leucocytes do roll on activated endothelium but they are not firmly attached, owing to the lack of Ang-2-dependent upregulation of adhesion molecules and the dominance of Ang-1-regulated suppression of adhesion molecules 120121122123125.

In bovine retinal pericytes, hypoxia and VEGF induce Ang-1 and Tie2 gene expression acutely without altering Ang-2 mRNA levels. The opposite occurs in bovine aortic ECs and microvascular ECs, underscoring the heterogeneity of ECs from different microvascular beds 73126127.

Lipopolysaccharide (LPS) and pro-inflammatory cytokines can shift the Ang/Tie balance, rouse ECs from quiescence and provoke an inflammatory response. In rodents LPS injection induces expression of Ang-2 mRNA and protein and reduces the levels of Ang-1, Tie2 and Tie2 phosphorylation in lung, liver and diaphragm within 24 hours, which may promote or maintain vascular leakage. The initial increase in permeability is probably due to release of Ang-2 stored in WPBs 39128. In a mouse model of LPS-induced lung injury, pulmonary oedema was found to be related to the balance between VEGF, Ang-1 and Ang-4 129. In a comparable model, Ang-1-producing transfected cells reduced alveolar inflammation and leakage 130.

In choroidal ECs, TNF induces Ang-2 mRNA and protein before affecting Ang-1 and VEGF levels 131. In HUVECs, TNF-induced upregulation of Ang-2 is mediated by the NF-κB pathway 132, and TNF-induced Tie2 expression can be attenuated by both Ang-1 and Ang-2. Without TNF stimulation, only Ang-1 can reduce Tie2 expression 133. Ang-2 sensitizes ECs to TNF, resulting in enhanced expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin 74125134. By inhibiting those endothelial adhesion molecules, Ang-1 decreases leucocyte adhesion 122.

Angiopoietins can mediate the synthesis of platelet-activating factor by ECs to stimulate inflammation 90. Moreover, both Ang-1 and Ang-2 can translocate P-selectin from WPBs to the surface of the EC 135, and both can also increase neutrophil adhesion and chemotaxis and enhance those processes when they are induced by interleukin-8 86136137.

In a rat model of haemorrhagic shock, Ang-1 reduced vascular leakage, and it inhibited microvascular endothelial cell apoptosis in vitro and in vivo 107138. In this model, Ang-1-promoted cell survival was partly controlled through integrin adhesion 139. It has been suggested that EC apoptosis in haemorrhagic shock contributes to endothelial hyperpermeability 140141142. Apoptosis is one of the reactions to MODS-related injury as demonstrated in hypoxia/reperfusion 143.

Cell adhesion

Ang-1 and Ang-2 are involved in cell-cell and cell-matrix binding 139144145146. Endothelial permeability is greatly dependent on cell-cell adhesion. The major adherens junction is largely composed of vascular-endothelial cadherin. This complex can be disrupted by VEGF, leading to increased vascular permeability 147148, which can be antagonized by Ang-1 149150. ECs can also bind to the matrix through the binding of Ang-1 to integrins, which can mediate some of the effects of Ang-1 without Tie2 phosphorylation 146151. At low Ang-1 concentrations, integrin and Tie2 can cooperate to stabilize ECs 151. Ang-2 might play a role in inflammatory diseases such as vasculitis by disrupting the cell-cell junction and inducing denudation of the basal membrane 152. Ang-1 can mediate the translocation of Tie2 to endothelial cell-cell contacts and induce Tie2-Tie2 bridges with signal pathway activation, leading to diminished paracellular permeability 65.

Summary

In the mature vessel, Ang-1 acts as a paracrine signal to maintain a quiescent status quo, whereas Ang-2 induces or facilitates an autocrine EC response 74153. In general, Ang-1 can be viewed as a stabilizing messenger, causing continuous Tie2 phosphorylation, and Ang-2 as a destabilizing messenger preparing for action 17. Attempts to unravel the exact molecular mechanisms that control the system are complicated by microenvironment-dependent endothelial phenotypes and reactivity and by flow type-dependent reactions to dynamic changes 13154155. Hence, the EC must be viewed in the context of its surroundings – the pericyte at the abluminal site, and the blood and its constituents on the luminal site 64. The Ang/Tie system certainly functions as one of the junctions in signal transduction and plays a key role in multiple cellular processes, many of which have been linked to MODS.

Targeting the Ang/Tie system in critical illness

A therapy should intervene in the right place and at the right time, with the proper duration of action and without collateral damage 156157. The Ang/Tie system is involved in many processes and lies at the intersection of molecular mechanisms of disease. Thus, interventions targeting this system might have benefits. As in other pleiotropic systems, however, unexpected and unwanted side effects are a serious risk. The absence of redundant systems to take over the function of Ang/Tie2 has the advantage that the effect of therapeutic intervention cannot easily be bypassed by the cell. On the other hand, because the cell has no escape, the effect may become uncontrolled and irreversible. Moreover, the exact function of the Ang/Tie system in the pathological cascade is not fully established. What we see in animal models and in patients is most probably the systemic reflection of a local process. We do not know whether this systemic reflection is just a marker of organ injury or even a mediator of distant organ involvement.

Of the three main functions of the Ang/Tie system, it is mainly angiogenesis that has been evaluated as a therapeutic target. So far, the focus of Ang/Tie modulation has been on inhibiting angiogenesis related to malignant and ophthalmological diseases and to complications of diabetes 158159. In peripheral arterial occlusive disease, stimulation of angiogenesis seems a logical strategy to attenuate the consequences of ongoing tissue ischaemia. In a rat model of hind limb ischaemia, combined delivery of Ang-1 and VEGF genes stimulated collateral vessel development to the greatest extent 160161. Thus far, therapy directed at VEGF has reached the clinic, but not therapy directed at Ang/Tie 162.

Targeting homeostasis and repair/inflammation in critically ill patients is an attractive option and has already led to the development of new drugs 45158163. From current knowledge, one can speculate about the best options for therapy aimed at the Ang/Tie system. In critical illness, Ang-1 is considered to be the 'good guy' because it can create vascular stability and thus its activity should be supported. In contrast, Ang-2 appears to be a 'bad guy' that induces vascular leakage, so its activity should be inhibited 164.

Production of recombinant Ang-1 is technically challenging as Ang-1 is 'sticky' because of its high affinity for the extracellular matrix 165. However, stable Ang-1 variants with improved receptor affinity have been engineered. A stable soluble Ang-1 variant has anti-permeability activity 165. When injected intraperitoneally in mice, human recombinant Ang-1 can prevent LPS-induced lung hyperpermeability 80. In diabetic mice, a stable Ang-1 derivative attenuated proteinuria and delayed renal failure 166, and manipulating the Ang-1/Ang-2 ratio changed infarct size 167. A more profound Ang-1 effect can be achieved by locally stimulating Ang-1 production. In experimental acute respiratory distress syndrome, transfected cells expressing Ang-1 reduced alveolar inflammation and leakage 130. An adenovirus construct encoding Ang-1 protected mice from death in an LPS model, and Ang-1 gene therapy reduced acute lung injury in a rat model 21168169. In hypertensive rats, a plasmid expressing a stable Ang-1 protein reduced blood pressure and end-organ damage 170. If used in a disease with a limited duration, as critical illness should be, virus/plasmid-driven production of Ang-1 could easily be shut down when it is no longer needed.

Manipulating Ang-2 activity is also difficult. Ang-2 stored in WPBs is rapidly released and must be captured immediately to prevent autocrine/paracrine disruption of protective Ang-1/Tie signalling. Soluble Tie2 or Ang-2 inhibitors should be effective 26171. Neutralizing antibodies against Ang-2 might also be an option. Replenishment of Ang-2 stores could be abolished by small interfering RNA techniques or spiegelmer/aptamer approaches 25172173.

However, no bad guy is all bad, and no good guy is all good. For example, Ang-1 has been linked to the development of pulmonary hypertension 174. Also, under certain circumstances Ang-2 can act as a Tie2 agonist and exert effects similar to those of Ang-1 – an unexplained finding that illustrates our limited understanding of the Ang/Tie system 75. Complete blockade of Ang-2 might also hamper innate immunity and revascularization.

Finding the right balance and timing will be the major challenge when developing therapies to target the Ang/Tie system. In the meantime, we might have already used Ang/Tie-directed therapy with the most pleiotropic of all drugs – corticosteroids. In the airways, steroids suppressed Ang-2 and increased Ang-1 expression 26171175. Interventions further downstream targeting specific adaptor molecules, signalling pathways, or transcription factors have yet to be explored.

Diagnostic and prognostic opportunities

In patients with malignant disease, the Ang/Tie system might serve as a tumour or response marker. In patients with multiple myeloma, normalization of the Ang-1/Ang-2 ratio reflects a response to treatment with anti-angiogenesis medication 176. In patients with non-small-cell lung cancer, Ang-2 is increased in serum and indicates tumour progression 177. After allogeneic stem cell transplantation in patients with high-risk myeloid malignancies, the serum Ang-2 concentration predicts disease-free survival 178, possibly reflecting a relation between cancer-driven angiogenesis and Ang-2 serum level.

In nonmalignant disease, the levels of Ang/Tie system components correlate with disease severity 28293435363739. However, current data are insufficient to justify the use of serum soluble Tie2/Ang levels for diagnostic and prognostic purposes. In critical illness, assessment of the Ang/Tie system in patients with different severities of disease and with involvement of different organ systems might help to define our patient population and allow us to rethink our concepts of MODS. In this way, such work may lead to enhanced diagnosis and prognostication in the future 2.

Conclusion

Accumulating evidence from animal and human studies points to the involvement of the Ang/Tie system in vascular barrier dysfunction during critical illness. Many processes in injury and in repair act through this nonredundant system. Thus far, only preliminary studies in critically ill patients have been reported. Methods to manipulate this system are available but have not been tested in such patients. The response to treatment is difficult to predict because of the pleiotropic functions of the Ang/Tie system, because the balance among its components appears to be more important than the absolute levels, and because the sensitivity of the endothelium to disease-related stimuli varies, depending on the environment and the organ involved. To avoid disappointment, further experimental and translational research must be carried out, and Ang/Tie modulation must not be introduced into the clinic prematurely. Implementing the results of this research in critical care represents an opportunity to show what we have learned 2. Ang/Tie signalling is a very promising target and must not be allowed to become lost in translation 179.

Abbreviations

Ang: angiopoietin; Ang/Tie system: angiopoietin/Tie2 signalling system; EC: endothelial cell; HUVEC: human umbilical vein endothelial cell; LPS: lipopolysaccharide; MODS: multiple organ dysfunction syndrome; NF-κB: nuclear factor-κB; PI3K: phosphoinositide-3 kinase; TNF: tumour necrosis factor; VEGF: vascular endothelial growth factor; WPB: Weibel-Palade body.

Competing interests

The authors declare that they have no competing interests.

Treating sepsis Wenzel RP N Engl J Med 2002 347 966 967 10.1056/NEJMp020096 12324551 Sepsis: rethinking the approach to clinical research Marshall JC J Leukoc Biol 2008 83 471 482 10.1189/jlb.0607380 18171697 Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation Singer M De Santis V Vitale D Jeffcoate W Lancet 2004 364 545 548 10.1016/S0140-6736(04)16815-3 15302200 Sir Isaac Newton, sepsis, SIRS, and CARS Bone RC Crit Care Med 1996 24 1125 1128 10.1097/00003246-199607000-00010 8674323 Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction Hotchkiss RS Swanson PE Freeman BD Tinsley KW Cobb JP Matuschak GM Buchman TG Karl IE Crit Care Med 1999 27 1230 1251 10.1097/00003246-199907000-00002 10446814 NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha Rius J Guma M Schachtrup C Akassoglou K Zinkernagel AS Nizet V Johnson RS Haddad GG Karin M Nature 2008 453 807 811 10.1038/nature06905 18432192 Efficacy and safety of recombinant human activated protein C for severe sepsis Bernard GR Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr N Engl J Med 2001 344 699 709 10.1056/NEJM200103083441001 11236773 Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock Annane D Sebille V Charpentier C Bollaert PE Francois B Korach JM Capellier G Cohen Y Azoulay E Troche G Chaumet-Riffaut P Bellissant E JAMA 2002 288 862 871 10.1001/jama.288.7.862 12186604 Intensive insulin therapy in the critically ill patients Berghe Van den G Wouters P Weekers F Verwaest C Bruyninckx F Schetz M Vlasselaers D Ferdinande P Lauwers P Bouillon R N Engl J Med 2001 345 1359 1367 10.1056/NEJMoa011300 11794168 Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms Aird WC Circ Res 2007 100 158 173 10.1161/01.RES.0000255691.76142.4a 17272818 Phenotypic heterogeneity of the endothelium: II. Representative vascular beds Aird WC Circ Res 2007 100 174 190 10.1161/01.RES.0000255690.03436.ae 17272819 Early organ-specific endothelial activation during hemorrhagic shock and resuscitation van Meurs M Wulfert FM Knol AJ de Haes A Houwertjes M Aarts LP Molema G Shock 2008 29 291 299 10.1097/shk.0b013e318145a7c1 17704730 Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer Langenkamp E Molema G Cell Tissue Res 2009 335 205 222 10.1007/s00441-008-0642-4 18677515 The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome Aird WC Blood 2003 101 3765 3777 10.1182/blood-2002-06-1887 12543869 A review on pro- and anti-angiogenic factors as targets of clinical intervention Bouis D Kusumanto Y Meijer C Mulder NH Hospers GA Pharmacol Res 2006 53 89 103 10.1016/j.phrs.2005.10.006 16321545 Increased circulating endothelial progenitor cells in septic patients: correlation with survival Rafat N Hanusch C Brinkkoetter PT Schulte J Brade J Zijlstra JG Woude van der FJ van AK Yard BA Beck GC Crit Care Med 2007 35 1677 1684 10.1097/01.CCM.0000269034.86817.59 17522579 Signaling and functions of angiopoietin-1 in vascular protection Brindle NP Saharinen P Alitalo K Circ Res 2006 98 1014 1023 2270395 16645151 10.1161/01.RES.0000218275.54089.12 Not just angiogenesis: wider roles for the angiopoietins Jones PF J Pathol 2003 201 515 527 10.1002/path.1452 14648654 Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia Davis B Dei CA Long DA White KE Hayward A Ku CH Woolf AS Bilous R Viberti G Gnudi L J Am Soc Nephrol 2007 18 2320 2329 10.1681/ASN.2006101093 17625119 Angiopoietin 1 and 2 gene and protein expression is differentially regulated in acute anti-Thy1.1 glomerulonephritis Campean V Karpe B Haas C Atalla A Peters H Rupprecht H Liebner S Acker T Plate K Amann K Am J Physiol Renal Physiol 2008 294 F1174 F1184 10.1152/ajprenal.00320.2007 18272601 Cell-based angiopoietin-1 gene therapy for acute lung injury McCarter SD Mei SH Lai PF Zhang QW Parker CH Suen RS Hood RD Zhao YD Deng Y Han RN Dumont DJ Stewart DJ Am J Respir Crit Care Med 2007 175 1014 1026 10.1164/rccm.200609-1370OC 17322110 Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma Simoes DC Vassilakopoulos T Toumpanakis D Petrochilou K Roussos C Papapetropoulos A Am J Respir Crit Care Med 2008 177 1314 1321 10.1164/rccm.200708-1141OC 18356565 Role of angiopoietin-1 in experimental and human pulmonary arterial hypertension Kugathasan L Dutly AE Zhao YD Deng Y Robb MJ Keshavjee S Stewart DJ Chest 2005 128 6 suppl 633S 642S 10.1378/chest.128.6_suppl.633S 16373885 Angiopoietin-1 and pulmonary hypertension: cause or cure? Rudge JS Thurston G Yancopoulos GD Circ Res 2003 92 947 949 10.1161/01.RES.0000074031.94558.99 12750304 Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death Bhandari V Choo-Wing R Lee CG Zhu Z Nedrelow JH Chupp GL Zhang X Matthay MA Ware LB Homer RJ Lee PJ Geick A de Fougerolles AR Elias JA Nat Med 2006 12 1286 1293 10.1038/nm1494 17086189 Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients Kanazawa H Nomura S Asai K Chest 2007 131 1035 1041 10.1378/chest.06-2758 17426207 Angiopoietin-2 levels are elevated in exudative pleural effusions Kalomenidis I Kollintza A Sigala I Papapetropoulos A Papiris S Light RW Roussos C Chest 2006 129 1259 1266 10.1378/chest.129.5.1259 16685017 Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans Parikh SM Mammoto T Schultz A Yuan HT Christiani D Karumanchi SA Sukhatme VP PLoS Med 2006 3 e46 1334221 16417407 10.1371/journal.pmed.0030046 Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome Gallagher DC Parikh SM Balonov K Miller A Gautam S Talmor D Sukhatme VP Shock 2008 29 656 661 10.1097/SHK.0b013e31815dd92f 18091573 Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? Choudhury A Freestone B Patel J Lip GY Chest 2007 132 1913 1919 10.1378/chest.07-1565 18079224 Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)] Nadar SK Blann A Beevers DG Lip GY J Intern Med 2005 258 336 343 10.1111/j.1365-2796.2005.01550.x 16164572 Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure Chong AY Caine GJ Freestone B Blann AD Lip GY J Am Coll Cardiol 2004 43 423 428 10.1016/j.jacc.2003.08.042 15013125 Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes Lee KW Lip GY Blann AD Circulation 2004 110 2355 2360 10.1161/01.CIR.0000138112.90641.7F 15302795 Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ganter MT Cohen MJ Brohi K Chesebro BB Staudenmayer KL Rahn P Christiaans SC Bir ND Pittet JF Ann Surg 2008 247 320 326 10.1097/SLA.0b013e318162d616 18216540 Admission angiopoietin levels in children with septic shock Giuliano JS Jr Lahni PM Harmon K Wong HR Doughty LA Carcillo JA Zingarelli B Sukhatme VP Parikh SM Wheeler DS Shock 2007 28 650 654 18092380 Circulating angiopoietin-1 and -2 in critically ill patients – development and clinical application of two new immunoassays Lukasz A Hellpap J Horn R Kielstein JT David S Haller H Kumpers P Crit Care 2008 12 R94 2575578 18664247 10.1186/cc6966 Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators Orfanos SE Kotanidou A Glynos C Athanasiou C Tsigkos S Dimopoulou I Sotiropoulou C Zakynthinos S Armaganidis A Papapetropoulos A Roussos C Crit Care Med 2007 35 199 206 10.1097/01.CCM.0000251640.77679.D7 17110873 Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis Siner JM Bhandari V Engle KM Elias JA Siegel MD Shock 2008 18791490 Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients Heijden van der M Nieuw Amerongen GP Koolwijk P van Hinsbergh VW Groeneveld AB Thorax 2008 63 903 909 10.1136/thx.2007.087387 18559364 A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis Shapiro NI Yano K Okada H Fischer C Howell M Spokes KC Ngo L Angus DC Aird WC Shock 2008 29 452 457 10.1097/SHK.0b013e31815072c1 18598002 Plasma vascular endothelial growth factor in severe sepsis Flier van der M van Leeuwen HJ van Kessel KP Kimpen JL Hoepelman AI Geelen SP Shock 2005 23 35 38 10.1097/01.shk.0000150728.91155.41 15614129 Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability Pickkers P Sprong T Eijk L Hoeven van der H Smits P Deuren M Shock 2005 24 508 512 10.1097/01.shk.0000190827.36406.6e 16317379 Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Suri C Jones PF Patan S Bartunkova S Maisonpierre PC Davis S Sato TN Yancopoulos GD Cell 1996 87 1171 1180 10.1016/S0092-8674(00)81813-9 8980224 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Maisonpierre PC Suri C Jones PF Bartunkova S Wiegand SJ Radziejewski C Compton D McClain J Aldrich TH Papadopoulos N Daly TJ Davis S Sato TN Yancopoulos GD Science 1997 277 55 60 10.1126/science.277.5322.55 9204896 Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease Makinde T Agrawal DK J Cell Mol Med 2008 12 810 828 10.1111/j.1582-4934.2008.00254.x 18266978 Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Davis S Aldrich TH Jones PF Acheson A Compton DL Jain V Ryan TE Bruno J Radziejewski C Maisonpierre PC Yancopoulos GD Cell 1996 87 1161 1169 10.1016/S0092-8674(00)81812-7 8980223 Tie receptors: new modulators of angiogenic and lymphangiogenic responses Jones N Iljin K Dumont DJ Alitalo K Nat Rev Mol Cell Biol 2001 2 257 267 10.1038/35067005 11283723 Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2 Kim KT Choi HH Steinmetz MO Maco B Kammerer RA Ahn SY Kim HZ Lee GM Koh GY J Biol Chem 2005 280 20126 20131 10.1074/jbc.M500292200 15769741 Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering Davis S Papadopoulos N Aldrich TH Maisonpierre PC Huang T Kovac L Xu A Leidich R Radziejewska E Rafique A Goldberg J Jain V Bailey K Karow M Fandl J Samuelsson SJ Ioffe E Rudge JS Daly TJ Radziejewski C Yancopoulos GD Nat Struct Biol 2003 10 38 44 10.1038/nsb880 12469114 Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization Bogdanovic E Nguyen VP Dumont DJ J Cell Sci 2006 119 3551 3560 10.1242/jcs.03077 16895971 Functional significance of Tie2 signaling in the adult vasculature Peters KG Kontos CD Lin PC Wong AL Rao P Huang L Dewhirst MW Sankar S Recent Prog Horm Res 2004 59 51 71 10.1210/rp.59.1.51 14749497 Structure of the extracellular domain of Tie receptor tyrosine kinases and localization of the angiopoietin-binding epitope Macdonald PR Progias P Ciani B Patel S Mayer U Steinmetz MO Kammerer RA J Biol Chem 2006 281 28408 28414 10.1074/jbc.M605219200 16849318 Protein tyrosine kinase structure and function Hubbard SR Till JH Annu Rev Biochem 2000 69 373 398 10.1146/annurev.biochem.69.1.373 10966463 Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling Eklund L Olsen BR Exp Cell Res 2006 312 630 641 10.1016/j.yexcr.2005.09.002 16225862 Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration Jones N Master Z Jones J Bouchard D Gunji Y Sasaki H Daly R Alitalo K Dumont DJ J Biol Chem 1999 274 30896 30905 10.1074/jbc.274.43.30896 10521483 Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood Reusch P Barleon B Weindel K Martiny-Baron G Godde A Siemeister G Marme D Angiogenesis 2001 4 123 131 10.1023/A:1012226627813 11806244 VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling Findley CM Cudmore MJ Ahmed A Kontos CD Arterioscler Thromb Vasc Biol 2007 27 2619 2626 10.1161/ATVBAHA.107.150482 17901375 Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2 Marron MB Singh H Tahir TA Kavumkal J Kim HZ Koh GY Brindle NP J Biol Chem 2007 282 30509 30517 2270410 17728252 10.1074/jbc.M702535200 Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival Yuan HT Venkatesha S Chan B Deutsch U Mammoto T Sukhatme VP Woolf AS Karumanchi SA FASEB J 2007 21 3171 3183 10.1096/fj.07-8487com 17504972 Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells Kim KL Shin IS Kim JM Choi JH Byun J Jeon ES Suh W Kim DK Cardiovasc Res 2006 72 394 402 10.1016/j.cardiores.2006.08.002 17054925 Functional symbiosis between endothelium and epithelial cells in glomeruli Hirschberg R Wang S Mitu GM Cell Tissue Res 2008 331 485 493 10.1007/s00441-007-0526-z 17999087 Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues Wong AL Haroon ZA Werner S Dewhirst MW Greenberg CS Peters KG Circ Res 1997 81 567 574 9314838 Endothelial/pericyte interactions Armulik A Abramsson A Betsholtz C Circ Res 2005 97 512 523 10.1161/01.RES.0000182903.16652.d7 16166562 The role of pericytes in blood-vessel formation and maintenance Bergers G Song S Neuro Oncol 2005 7 452 464 1871727 16212810 10.1215/S1152851705000232 Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts Saharinen P Eklund L Miettinen J Wirkkala R Anisimov A Winderlich M Nottebaum A Vestweber D Deutsch U Koh GY Olsen BR Alitalo K Nat Cell Biol 2008 10 527 537 10.1038/ncb1715 18425119 Formation and function of Weibel-Palade bodies Metcalf DJ Nightingale TD Zenner HL Lui-Roberts WW Cutler DF J Cell Sci 2008 121 19 27 10.1242/jcs.03494 18096688 The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies Fiedler U Scharpfenecker M Koidl S Hegen A Grunow V Schmidt JM Kriz W Thurston G Augustin HG Blood 2004 103 4150 4156 10.1182/blood-2003-10-3685 14976056 Dynamics and plasticity of Weibel-Palade bodies in endothelial cells Rondaij MG Bierings R Kragt A van Mourik JA Voorberg J Arterioscler Thromb Vasc Biol 2006 26 1002 1007 10.1161/01.ATV.0000209501.56852.6c 16469951 Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2 Lewis CE De PM Naldini L Cancer Res 2007 67 8429 8432 10.1158/0008-5472.CAN-07-1684 17875679 Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications De Palma M Murdoch C Venneri MA Naldini L Lewis CE Trends Immunol 2007 28 519 524 10.1016/j.it.2007.09.004 17981504 Localization of Tie2 and phospholipase D in endothelial caveolae is involved in angiopoietin-1-induced MEK/ERK phosphorylation and migration in endothelial cells Yoon MJ Cho CH Lee CS Jang IH Ryu SH Koh GY Biochem Biophys Res Commun 2003 308 101 105 10.1016/S0006-291X(03)01341-X 12890486 Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2 Ward EG Grosios K Markham AF Jones PF Cytogenet Cell Genet 2001 94 147 154 10.1159/000048807 11856872 Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells Oh H Takagi H Suzuma K Otani A Matsumura M Honda Y J Biol Chem 1999 274 15732 15739 10.1074/jbc.274.22.15732 10336473 Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia Mandriota SJ Pepper MS Circ Res 1998 83 852 859 9776732 Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells Daly C Pasnikowski E Burova E Wong V Aldrich TH Griffiths J Ioffe E Daly TJ Fandl JP Papadopoulos N McDonald DM Thurston G Yancopoulos GD Rudge JS Proc Natl Acad Sci USA 2006 103 15491 15496 1592534 17030814 10.1073/pnas.0607538103 Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements Hegen A Koidl S Weindel K Marme D Augustin HG Fiedler U Arterioscler Thromb Vasc Biol 2004 24 1803 1809 10.1161/01.ATV.0000140819.81839.0e 15284088 Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1 Hasegawa Y Abe M Yamazaki T Niizeki O Shiiba K Sasaki I Sato Y Biochem Biophys Res Commun 2004 316 52 58 10.1016/j.bbrc.2004.02.019 15003510 Internal translation initiation mediated by the angiogenic factor Tie2 Park EH Lee JM Blais JD Bell JC Pelletier J J Biol Chem 2005 280 20945 20953 10.1074/jbc.M412744200 15802272 Signaling mechanisms regulating endothelial permeability Mehta D Malik AB Physiol Rev 2006 86 279 367 10.1152/physrev.00012.2005 16371600 Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo Mammoto T Parikh SM Mammoto A Gallagher D Chan B Mostoslavsky G Ingber DE Sukhatme VP J Biol Chem 2007 282 23910 23918 10.1074/jbc.M702169200 17562701 Transcriptome of angiopoietin 1-activated human umbilical vein endothelial cells Abdel-Malak NA Harfouche R Hussain SN Endothelium 2007 14 285 302 10.1080/10623320701678268 18080866 Gene expression analysis of Tek/Tie2 signaling Chen SH Babichev Y Rodrigues N Voskas D Ling L Nguyen VP Dumont DJ Physiol Genomics 2005 22 257 267 10.1152/physiolgenomics.00063.2005 15899944 Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide Babaei S Teichert-Kuliszewska K Zhang Q Jones N Dumont DJ Stewart DJ Am J Pathol 2003 162 1927 1936 1868142 12759249 Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells Harfouche R Hassessian HM Guo Y Faivre V Srikant CB Yancopoulos GD Hussain SN Microvasc Res 2002 64 135 147 10.1006/mvre.2002.2421 12074640 Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion Kim I Kim HG Moon SO Chae SW So JN Koh KN Ahn BC Koh GY Circ Res 2000 86 952 959 10807867 Angiopoietin chemotactic activities on neutrophils are regulated by PI-3K activation Brkovic A Pelletier M Girard D Sirois MG J Leukoc Biol 2007 81 1093 1101 10.1189/jlb.0906580 17215522 Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases Harfouche R Gratton JP Yancopoulos GD Noseda M Karsan A Hussain SN FASEB J 2003 17 1523 1525 12824293 Signaling and regulation of endothelial cell survival by angiopoietin-2 Harfouche R Hussain SN Am J Physiol Heart Circ Physiol 2006 291 H1635 H1645 10.1152/ajpheart.01318.2005 16714355 Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway Kim I Kim JH Moon SO Kwak HJ Kim NG Koh GY Oncogene 2000 19 4549 4552 10.1038/sj.onc.1203800 11002428 Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: intracellular signalling pathways Maliba R Lapointe S Neagoe PE Brkovic A Sirois MG Cell Signal 2006 18 1947 1957 10.1016/j.cellsig.2006.02.015 16617006 Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8 Abdel-Malak NA Srikant CB Kristof AS Magder SA Di Battista JA Hussain SN Blood 2008 111 4145 4154 10.1182/blood-2007-08-110338 18252863 Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) Daly C Wong V Burova E Wei Y Zabski S Griffiths J Lai KM Lin HC Ioffe E Yancopoulos GD Rudge JS Genes Dev 2004 18 1060 1071 406295 15132996 10.1101/gad.1189704 ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1 Tadros A Hughes DP Dunmore BJ Brindle NP Blood 2003 102 4407 4409 10.1182/blood-2003-05-1602 12933576 Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling Harfouche R Malak NA Brandes RP Karsan A Irani K Hussain SN FASEB J 2005 19 1728 1730 16049136 Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1 Fukuhara S Sako K Minami T Noda K Kim HZ Kodama T Shibuya M Takakura N Koh GY Mochizuki N Nat Cell Biol 2008 10 513 526 10.1038/ncb1714 18425120 Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo Lobov IB Brooks PC Lang RA Proc Natl Acad Sci USA 2002 99 11205 11210 123234 12163646 10.1073/pnas.172161899 Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2 Nguyen VP Chen SH Trinh J Kim H Coomber BL Dumont DJ BMC Cell Biol 2007 8 10 1828055 17341311 10.1186/1471-2121-8-10 Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2 Teichert-Kuliszewska K Maisonpierre PC Jones N Campbell AI Master Z Bendeck MP Alitalo K Dumont DJ Yancopoulos GD Stewart DJ Cardiovasc Res 2001 49 659 670 10.1016/S0008-6363(00)00231-5 11166279 Angiogenesis and inflammation face off Imhof BA urrand-Lions M Nat Med 2006 12 171 172 10.1038/nm0206-171 16462798 Innate immunity and angiogenesis Frantz S Vincent KA Feron O Kelly RA Circ Res 2005 96 15 26 10.1161/01.RES.0000153188.68898.ac 15637304 Transcriptional regulators of angiogenesis Hamik A Wang B Jain MK Arterioscler Thromb Vasc Biol 2006 26 1936 1947 10.1161/01.ATV.0000232542.42968.e3 16778118 Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression Davis GE Senger DR Curr Opin Hematol 2008 15 197 203 10.1097/MOH.0b013e3282fcc321 18391785 The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism Scharpfenecker M Fiedler U Reiss Y Augustin HG J Cell Sci 2005 118 771 780 10.1242/jcs.01653 15687104 Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis Aplin AC Gelati M Fogel E Carnevale E Nicosia RF Physiol Genomics 2006 27 20 28 10.1152/physiolgenomics.00048.2006 17018690 Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells Uemura A Ogawa M Hirashima M Fujiwara T Koyama S Takagi H Honda Y Wiegand SJ Yancopoulos GD Nishikawa S J Clin Invest 2002 110 1619 1628 151628 12464667 Contextual role for angiopoietins and TGFbeta1 in blood vessel stabilization Ramsauer M D'Amore PA J Cell Sci 2007 120 1810 1817 10.1242/jcs.003533 17502485 Angiopoietin-1 is an apoptosis survival factor for endothelial cells Kwak HJ So JN Lee SJ Kim I Koh GY FEBS Lett 1999 448 249 253 10.1016/S0014-5793(99)00378-6 10218485 Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors Papapetropoulos A Garcia-Cardena G Dengler TJ Maisonpierre PC Yancopoulos GD Sessa WC Lab Invest 1999 79 213 223 10068209 Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway Papapetropoulos A Fulton D Mahboubi K Kalb RG O'Connor DS Li F Altieri DC Sessa WC J Biol Chem 2000 275 9102 9105 10.1074/jbc.275.13.9102 10734041 Cyclic strain regulates the Notch/CBF-1 signaling pathway in endothelial cells: role in angiogenic activity Morrow D Cullen JP Cahill PA Redmond EM Arterioscler Thromb Vasc Biol 2007 27 1289 1296 10.1161/ATVBAHA.107.142778 17395855 Expression of Tie-2 by human monocytes and their responses to angiopoietin-2 Murdoch C Tazzyman S Webster S Lewis CE J Immunol 2007 178 7405 7411 17513791 Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells Chen-Konak L Guetta-Shubin Y Yahav H Shay-Salit A Zilberman M Binah O Resnick N FASEB J 2003 17 2121 2123 14500555 Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2 Witzenbichler B Maisonpierre PC Jones P Yancopoulos GD Isner JM J Biol Chem 1998 273 18514 18521 10.1074/jbc.273.29.18514 9660821 Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch Rao S Lobov IB Vallance JE Tsujikawa K Shiojima I Akunuru S Walsh K Benjamin LE Lang RA Development 2007 134 4449 4458 10.1242/dev.012187 18039971 Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage Roviezzo F Tsigkos S Kotanidou A Bucci M Brancaleone V Cirino G Papapetropoulos A J Pharmacol Exp Ther 2005 314 738 744 10.1124/jpet.105.086553 15870388 Expressional regulation of the angiopoietin-1 and -2 and the endothelial-specific receptor tyrosine kinase Tie2 in adrenal atrophy: a study of adrenocorticotropin-induced repair Feraud O Mallet C Vilgrain I Endocrinology 2003 144 4607 4615 10.1210/en.2003-0099 12960064 Angiopoietins: a link between angiogenesis and inflammation Fiedler U Augustin HG Trends Immunol 2006 27 552 558 10.1016/j.it.2006.10.004 17045842 Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules Baffert F Le T Thurston G McDonald DM Am J Physiol Heart Circ Physiol 2006 290 H107 H118 10.1152/ajpheart.00542.2005 16126815 Angiopoietin-1 protects the adult vasculature against plasma leakage Thurston G Rudge JS Ioffe E Zhou H Ross L Croll SD Glazer N Holash J McDonald DM Yancopoulos GD Nat Med 2000 6 460 463 10.1038/74725 10742156 Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells Kim I Oh JL Ryu YS So JN Sessa WC Walsh K Koh GY FASEB J 2002 16 126 128 11729102 Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions Gamble JR Drew J Trezise L Underwood A Parsons M Kasminkas L Rudge J Yancopoulos G Vadas MA Circ Res 2000 87 603 607 11009566 Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression Kim I Moon SO Park SK Chae SW Koh GY Circ Res 2001 89 477 479 10.1161/hh1801.097034 11557733 Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production Pizurki L Zhou Z Glynos K Roussos C Papapetropoulos A Br J Pharmacol 2003 139 329 336 1573855 12770938 10.1038/sj.bjp.0705259 Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties Satchell SC Anderson KL Mathieson PW J Am Soc Nephrol 2004 15 566 574 10.1097/01.ASN.0000115397.22519.03 14978158 Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation Fiedler U Reiss Y Scharpfenecker M Grunow V Koidl S Thurston G Gale NW Witzenrath M Rosseau S Suttorp N Sobke A Herrmann M Preissner KT Vajkoczy P Augustin HG Nat Med 2006 12 235 239 10.1038/nm1351 16462802 Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes Park YS Kim NH Jo I Microvasc Res 2003 65 125 131 10.1016/S0026-2862(02)00035-3 12686170 Hypoxic regulation of angiopoietin-2 expression in endothelial cells Pichiule P Chavez JC LaManna JC J Biol Chem 2004 279 12171 12180 10.1074/jbc.M305146200 14702352 Regulation of angiopoietin expression by bacterial lipopolysaccharide Mofarrahi M Nouh T Qureshi S Guillot L Mayaki D Hussain SN Am J Physiol Lung Cell Mol Physiol 2008 294 L955 L963 10.1152/ajplung.00449.2007 18310225 Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury Karmpaliotis D Kosmidou I Ingenito EP Hong K Malhotra A Sunday ME Haley KJ Am J Physiol Lung Cell Mol Physiol 2002 283 L585 L595 12169578 Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1 Mei SH McCarter SD Deng Y Parker CH Liles WC Stewart DJ PLoS Med 2007 4 e269 1961632 17803352 10.1371/journal.pmed.0040269 Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells Hangai M He S Hoffmann S Lim JI Ryan SJ Hinton DR J Neuroimmunol 2006 171 45 56 10.1016/j.jneuroim.2005.09.018 16288810 Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells Kim I Kim JH Ryu YS Liu M Koh GY Biochem Biophys Res Commun 2000 269 361 365 10.1006/bbrc.2000.2296 10708557 Regulation of tie2 expression by angiopoietin – potential feedback system Hashimoto T Wu Y Boudreau N Li J Matsumoto M Young W Endothelium 2004 11 207 210 10.1080/10623320490512417 15370298 Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2 Mangan SH Campenhout AV Rush C Golledge J Cardiovasc Res 2007 76 494 505 2128766 17706953 10.1016/j.cardiores.2007.07.017 Angiopoietin-mediated endothelial P-selectin translocation: cell signaling mechanisms Maliba R Brkovic A Neagoe PE Villeneuve LR Sirois MG J Leukoc Biol 2008 83 352 360 10.1189/jlb.0107056 17984290 Ang-2 and PDGF-BB cooperatively stimulate human peripheral blood monocyte fibrinolysis Bezuidenhout L Bracher M Davison G Zilla P Davies N J Leukoc Biol 2007 81 1496 1503 10.1189/jlb.1106687 17395886 Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses Lemieux C Maliba R Favier J Theoret JF Merhi Y Sirois MG Blood 2005 105 1523 1530 10.1182/blood-2004-09-3531 15498854 Angiopoietin-1 inhibits intrinsic apoptotic signaling and vascular hyperpermeability following hemorrhagic shock Childs EW Tharakan B Byrge N Tinsley JH Hunter FA Smythe WR Am J Physiol Heart Circ Physiol 2008 294 H2285 H2295 10.1152/ajpheart.01361.2007 18344375 Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins Dallabrida SM Ismail N Oberle JR Himes BE Rupnick MA Circ Res 2005 96 e8 24 10.1161/01.RES.0000158285.57191.60 15692086 Apoptotic signaling induces hyperpermeability following hemorrhagic shock Childs EW Tharakan B Hunter FA Tinsley JH Cao X Am J Physiol Heart Circ Physiol 2007 292 H3179 H3189 10.1152/ajpheart.01337.2006 17307990 Alpha lipoic acid attenuates microvascular endothelial cell hyperpermeability by inhibiting the intrinsic apoptotic signaling Tharakan B Holder-Haynes JG Hunter FA Childs EW Am J Surg 2008 195 174 178 10.1016/j.amjsurg.2007.09.028 18096126 Traumahemorrhagic shock mesenteric lymph induces endothelial apoptosis that involves both caspase-dependent and caspase-independent mechanisms Davidson MT Deitch EA Lu Q Hasko G Abungu B Nemeth ZH Zaets SB Gaspers LD Thomas AP Xu DZ Ann Surg 2004 240 123 131 1356384 15213628 10.1097/01.sla.0000129341.94219.cf Rhokinase-dependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischemia-reperfusion-induced endothelial cell apoptosis Heijden van der M Versteilen AM Sipkema P van Nieuw Amerongen GP Musters RJ Groeneveld AB Apoptosis 2008 13 404 412 2257993 18165899 10.1007/s10495-007-0173-6 Besides adhesion: new perspectives of integrin functions in angiogenesis Serini G Napione L Arese M Bussolino F Cardiovasc Res 2008 78 213 222 10.1093/cvr/cvn045 18285512 Direct cell adhesion to the angiopoietins mediated by integrins Carlson TR Feng Y Maisonpierre PC Mrksich M Morla AO J Biol Chem 2001 276 26516 26525 10.1074/jbc.M100282200 11346644 Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization Weber CC Cai H Ehrbar M Kubota H Martiny-Baron G Weber W Djonov V Weber E Mallik AS Fussenegger M Frei K Hubbell JA Zisch AH J Biol Chem 2005 280 22445 22453 10.1074/jbc.M410367200 15781448 The role of adherens junctions and VE-cadherin in the control of vascular permeability Dejana E Orsenigo F Lampugnani MG J Cell Sci 2008 121 2115 2122 10.1242/jcs.017897 18565824 VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells Shay-Salit A Shushy M Wolfovitz E Yahav H Breviario F Dejana E Resnick N Proc Natl Acad Sci USA 2002 99 9462 9467 123163 12080144 10.1073/pnas.142224299 Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKC beta Wang Y Pampou S Fujikawa K Varticovski L J Cell Physiol 2004 198 53 61 10.1002/jcp.10386 14584044 Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia Gavard J Patel V Gutkind JS Dev Cell 2008 14 25 36 10.1016/j.devcel.2007.10.019 18194650 Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1 Cascone I Napione L Maniero F Serini G Bussolino F J Cell Biol 2005 170 993 1004 2171441 16157706 10.1083/jcb.200507082 Elevated serum angiopoietin-2 correlates with degree of arteriosclerosis in CKD V patients David S Kumpers P Hellpap J Horn R Holger L Kielstein JT Haller H J Am Soc Nephrol 2007 18 http://www.asn-online.org/education%5Fand5Fmeetings/renal%5fweek/archives/2007-abstract-archive.pdf SU-PO250 Emerging roles of the angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking Pfaff D Fiedler U Augustin HG J Leukoc Biol 2006 80 719 726 10.1189/jlb.1105652 16864601 Endothelial immunogenicity: a matter of matrix microarchitecture Methe H Hess S Edelman ER Thromb Haemost 2007 98 278 282 17721607 Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression Methe H Balcells M Alegret MC Santacana M Molins B Hamik A Jain MK Edelman ER Am J Physiol Heart Circ Physiol 2007 292 H2167 H2175 10.1152/ajpheart.00403.2006 17209004 Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Griffioen AW Molema G Pharmacol Rev 2000 52 237 268 10835101 Angiogenesis treatment, new concepts on the horizon Griffin RJ Molema G Dings RP Angiogenesis 2006 9 67 72 10.1007/s10456-006-9031-3 16964528 Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1 Niu Q Perruzzi C Voskas D Lawler J Dumont DJ Benjamin LE Cancer Biol Ther 2004 3 402 405 14739779 Tumor angiogenesis Kerbel RS N Engl J Med 2008 358 2039 2049 10.1056/NEJMra0706596 18463380 Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization Chae JK Kim I Lim ST Chung MJ Kim WH Kim HG Ko JK Koh GY Arterioscler Thromb Vasc Biol 2000 20 2573 2578 11116055 Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia Ryu JK Cho CH Shin HY Song SU Oh SM Lee M Piao S Han JY Kim IH Koh GY Suh JK Mol Ther 2006 13 705 715 10.1016/j.ymthe.2005.10.016 16380295 Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents Holash J Thurston G Rudge JS Yancopoulos GD Adjei AA Bergers G Pytowski B Pegram M Gordon MS Cancer Metastasis Rev 2006 25 243 252 10.1007/s10555-006-8504-6 16770536 Biomedical significance of endothelial cell specific growth factor, angiopoietin Koh GY Kim I Kwak HJ Yun MJ Leem JC Exp Mol Med 2002 34 1 11 11989972 Angiopoietin-2: modulator of vascular permeability in acute lung injury? Hashimoto T Pittet JF PLoS Med 2006 3 e113 1360081 16441182 10.1371/journal.pmed.0030113 COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity Cho CH Kammerer RA Lee HJ Steinmetz MO Ryu YS Lee SH Yasunaga K Kim KT Kim I Choi HH Kim W Kim SH Park SK Lee GM Koh GY Proc Natl Acad Sci USA 2004 101 5547 5552 397420 15060279 10.1073/pnas.0307574101 Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes Lee S Kim W Moon SO Sung MJ Kim DH Kang KP Jang KY Lee SY Park BH Koh GY Park SK Nephrol Dial Transplant 2007 22 396 408 10.1093/ndt/gfl598 17085463 Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis Tuo QH Zeng H Stinnett A Yu H Aschner JL Liao DF Chen JX Am J Physiol Heart Circ Physiol 2008 294 H2547 H2557 10.1152/ajpheart.01250.2007 18408125 Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization Thebaud B Ladha F Michelakis ED Sawicka M Thurston G Eaton F Hashimoto K Harry G Haromy A Korbutt G Archer SL Circulation 2005 112 2477 2486 10.1161/CIRCULATIONAHA.105.541524 16230500 Protective role of angiopoietin-1 in endotoxic shock Witzenbichler B Westermann D Knueppel S Schultheiss HP Tschope C Circulation 2005 111 97 105 10.1161/01.CIR.0000151287.08202.8E 15611372 Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor Lee JS Song SH Kim JM Shin IS Kim KL Suh YL Kim HZ Koh GY Byun J Jeon ES Suh W Kim DK Cardiovasc Res 2008 78 572 580 10.1093/cvr/cvn048 18285514 Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: attenuation by dexamethasone Aghai ZH Faqiri S Saslow JG Nakhla T Farhath S Kumar A Eydelman R Strande L Stahl G Leone P Bhandari V J Perinatol 2008 28 149 155 10.1038/sj.jp.7211886 18033304 Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer Sarraf-Yazdi S Mi J Moeller BJ Niu X White RR Kontos CD Sullenger BA Dewhirst MW Clary BM J Surg Res 2008 146 16 23 10.1016/j.jss.2007.04.028 17950331 Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? Grimm D Kay MA J Clin Invest 2007 117 3633 3641 2096424 18060021 10.1172/JCI34129 Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension Dewachter L Adnot S Fadel E Humbert M Maitre B Barlier-Mur AM Simonneau G Hamon M Naeije R Eddahibi S Am J Respir Crit Care Med 2006 174 1025 1033 10.1164/rccm.200602-304OC 16917117 Relationship between vascular endothelial growth factor and angio-poietin-2 in asthmatics before and after inhaled beclomethasone therapy Nomura S Kanazawa H Hirata K Iwao H Yoshikawa J J Asthma 2005 42 141 146 10.1081/JAS-200051346 15871447 Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib Anargyrou K Terpos E Vassilakopoulos TP Pouli A Sachanas S Tzenou T Masouridis S Christoulas D Angelopoulou MK Dimitriadou EM Kalpadakis C Tsionos K Panayiotidis P Dimopoulos MA Pangalis GA Kyrtsonis MC Haematologica 2008 93 451 454 10.3324/haematol.11852 18287135 Serum angiopoietin-2 as a clinical marker for lung cancer Park JH Park KJ Kim YS Sheen SS Lee KS Lee HN Oh YJ Hwang SC Chest 2007 132 200 206 10.1378/chest.06-2915 17505039 Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Kumpers P Koenecke C Hecker H Hellpap J Horn R Verhagen W Buchholz S Hertenstein B Krauter J Eder M David S Gohring G Haller H Ganser A Blood 2008 112 2139 2148 10.1182/blood-2007-12-130021 18483397 The full cycle Ledford H Nature 2008 453 843 845 10.1038/453843a 18548044 Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak Gallagher DC Bhatt RS Parikh SM Patel P Seery V McDermott DF Atkins MB Sukhatme VP Clin Cancer Res 2007 13 2115 2120 10.1158/1078-0432.CCR-06-2509 17404094 Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma Scholz A Rehm VA Rieke S Derkow K Schulz P Neumann K Koch I Pascu M Wiedenmann B Berg T Schott E Am J Gastroenterol 2007 102 2471 2481 10.1111/j.1572-0241.2007.01377.x 17581268